Skip to content
Menu

Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.

Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and raises the price target from $42 to $57.

Read at benzinga.com